MEIP - MEI Pharma, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
MEIP price evolution
MEIP
| (in millions $) | 30 Jul 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.17 | $3.37 | $16.91 | |
| Short term investments | $54.31 | $78.83 | $83.79 | |
| Net receivables | $0.09 | |||
| Inventory | ||||
| Total current assets | $66.17 | $88.42 | $107.53 | |
| Long term investments | ||||
| Property, plant & equipment | $12.37 | $12.83 | $13.28 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.37 | $12.83 | $13.28 | |
| Total investments | $54.31 | $78.83 | $83.79 | |
| Total assets | $78.54 | $101.25 | $120.81 | |
| Current liabilities | ||||
| Accounts payable | $1.38 | $3.22 | $6.13 | |
| Deferred revenue | $64.86 | |||
| Short long term debt | $1.01 | $1.05 | $1.43 | |
| Total current liabilities | $8.04 | $8.56 | $20.34 | |
| Long term debt | $11.01 | $11.33 | $11.3 | |
| Total noncurrent liabilities | $11.01 | $11.33 | $75.84 | |
| Total debt | $12.03 | $12.38 | $12.73 | |
| Total liabilities | $19.05 | $19.89 | $96.19 | |
| Shareholders' equity | ||||
| Retained earnings | -$360.69 | -$349.62 | -$406 | |
| Other shareholder equity | ||||
| Total shareholder equity | $59.49 | $81.36 | $24.62 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.91 | $153.25 | $153.43 | $182.63 |
| Short term investments | $83.79 | |||
| Net receivables | $0.09 | $10.04 | $7.58 | $20.42 |
| Inventory | ||||
| Total current assets | $107.53 | $167.13 | $164.82 | $208.64 |
| Long term investments | ||||
| Property, plant & equipment | $13.28 | $10.71 | $9.28 | $1.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $13.28 | $10.71 | $9.28 | $1.08 |
| Total investments | $83.79 | |||
| Total assets | $120.81 | $177.84 | $174.1 | $209.73 |
| Current liabilities | ||||
| Accounts payable | $6.13 | $7.92 | $6.36 | $2.44 |
| Deferred revenue | $64.86 | $95.44 | $87.33 | $82.5 |
| Short long term debt | $1.43 | $0.87 | $0.93 | |
| Total current liabilities | $20.34 | $24.44 | $30.29 | $23.3 |
| Long term debt | $11.3 | $8.77 | $7.37 | |
| Total noncurrent liabilities | $75.84 | $100.98 | $102.44 | $108.21 |
| Total debt | $12.73 | $9.64 | $8.3 | |
| Total liabilities | $96.19 | $125.43 | $132.74 | $131.51 |
| Shareholders' equity | ||||
| Retained earnings | -$406 | -$374.16 | -$327.81 | -$277.23 |
| Other shareholder equity | ||||
| Total shareholder equity | $24.62 | $52.41 | $41.36 | $78.22 |
| (in millions $) | 30 Jul 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $65.3 | $1.46 | ||
| Cost of revenue | ||||
| Gross Profit | $65.3 | $1.46 | ||
| Operating activities | ||||
| Research & development | $3.91 | $3.48 | $2.57 | |
| Selling, general & administrative | $8.02 | $6.53 | $9.97 | |
| Total operating expenses | $11.93 | $10.02 | $12.54 | |
| Operating income | -$11.93 | $55.28 | -$11.08 | |
| Income from continuing operations | ||||
| EBIT | -$11.06 | $56.37 | -$10.03 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$11.06 | $56.37 | -$10.03 | |
| Income (for common shares) | -$11.06 | $56.37 | -$10.03 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $48.82 | $40.7 | $25.54 | $28.91 |
| Cost of revenue | $1.41 | $2.67 | ||
| Gross Profit | $48.82 | $40.7 | $24.13 | $26.24 |
| Operating activities | ||||
| Research & development | $52.45 | $85.64 | $69.4 | $34.06 |
| Selling, general & administrative | $33.13 | $30.54 | $24.41 | $16.72 |
| Total operating expenses | $85.58 | $116.18 | $93.81 | $50.78 |
| Operating income | -$36.76 | -$75.48 | -$69.69 | -$24.54 |
| Income from continuing operations | ||||
| EBIT | -$31.84 | -$54.45 | -$50.57 | -$46.02 |
| Income tax expense | $0.01 | $0 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$31.84 | -$54.45 | -$50.58 | -$46.02 |
| Income (for common shares) | -$31.84 | -$54.45 | -$50.58 | -$46.02 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$11.06 | $56.37 | -$10.03 | -$15.44 |
| Operating activities | ||||
| Depreciation | $0.46 | $0.46 | $0.46 | $0.46 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.85 | $0.36 | $0.3 | $0.92 |
| Total cash flows from operations | -$11.05 | -$18.49 | -$11.3 | -$12.13 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.04 | -$0.01 | |
| Investments | $24.52 | $4.96 | $19.44 | $10.03 |
| Total cash flows from investing | $24.52 | $4.96 | $19.4 | $10.03 |
| Financing activities | ||||
| Dividends paid | -$11.66 | |||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$11.66 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.8 | -$13.53 | $8.09 | -$2.1 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$31.84 | -$54.45 | -$50.58 | -$46.02 |
| Operating activities | ||||
| Depreciation | $1.81 | $1.24 | $0.28 | $0.11 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.59 | $8.35 | $10.24 | $6.8 |
| Total cash flows from operations | -$52.48 | -$48.75 | -$31.96 | $34.26 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.48 | -$0.71 | -$0.89 |
| Investments | $53.73 | $7.37 | $25.42 | -$105.4 |
| Total cash flows from investing | $53.69 | $6.89 | $24.71 | -$106.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $52.9 | $3.47 | $74.78 | |
| Net borrowings | ||||
| Total cash flows from financing | -$0.04 | $49.05 | $3.47 | $74.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.17 | $7.2 | -$3.79 | $2.74 |
News
|
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance
14 Feb 2024
|
|
Is MEI Pharma (MEIP) Attractively Priced?
Insider Monkey via Yahoo Finance
8 Feb 2024
|
|
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
Zacks via Yahoo Finance
10 Nov 2023
|
|
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
Zacks via Yahoo Finance
8 Nov 2023
|
|
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
Zacks via Yahoo Finance
8 Nov 2023
|
|
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
Zacks via Yahoo Finance
3 Nov 2023
|
|
Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View
Zacks via Yahoo Finance
3 Nov 2023
|
|
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
Zacks
2 Nov 2023
|
|
Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up
Zacks via Yahoo Finance
2 Nov 2023
|
|
Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates
Zacks via Yahoo Finance
1 Nov 2023
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 3.91 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |